Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRP for Osteochondral Lesions of the Talus
NCT05795660Phase 1Not yet recruiting
- Sponsor
- Kuwait Ministry of Health
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Modality
- Adoptive Cell Transfer
01
Overview
Phase 1, randomised, double-blind trial of autologous platelet-rich plasma in osteochondral lesion of the talus (OLT) (2 arms), sponsored by Kuwait Ministry of Health. Primary endpoint: American Orthopedic Foot and Ankle Society Score at 12 months. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
autologous platelet-rich plasma
03
Conditions
osteochondral lesion of the talus (OLT)
Beyond the preview
Go deeper on NCT05795660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795660.